Orphan drug status accorded to antiobesity product

被引：0

|

作者：

不详

机构：

来源：

BIOTECHNOLOGY LAW REPORT | 1996年 / 15卷 / 04期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

收藏

页码：589 / 589

页数：1

相关论文

共 50 条

[1] GalioMedix and Orphan Drug Status
不详
[J]. JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (03) : 16N - 16N
[2] Orphan status for glioma drug
不详
[J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (07) : 804 - 804
[3] Orphan status for leukaemia drug
不详
[J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (01) : 1 - 1
[4] Orphan drug status for APL ...
不详
[J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (14) : 1969 - 1969
[5] Voraxaze receives orphan drug status
不详
[J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (06) : 709 - 709
[6] Zactima: towards orphan drug status
不详
[J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (04) : 428 - 428
[7] Orphan drug product regulation - United States
Haffner, ME
[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2002, 40 (02) : 84 - 88
[8] Another cytotoxic wins orphan drug status
不详
[J]. ANNALS OF ONCOLOGY, 2002, 13 (07) : 989 - 989
[9] Yondelis granted orphan drug status by Swissmedic
不详
[J]. EJHP PRACTICE, 2008, 14 (03): : 14 - 14
[10] Orphan drug status granted to trovert, spheramine, apomorphine
不详
[J]. BIOTECHNOLOGY LAW REPORT, 1997, 16 (5-6): : 554 - 555

← 1 2 3 4 5 →